# A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)

> **NCT00420784** · PHASE2 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 465 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** Telaprevir
- **DRUG:** Ribavirin
- **DRUG:** Pegylated Interferon Alfa 2a
- **DRUG:** Matching Placebo

## Key facts

- **NCT ID:** NCT00420784
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02
- **Primary completion:** 2008-12
- **Final completion:** 2009-04
- **Target enrollment:** 465 (ACTUAL)
- **Last updated:** 2014-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00420784

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00420784, "A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00420784. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*